Pfizer/Allergan: Breaking Up Is Hard To Do (Unless There’s A New Tax Law)
Executive Summary
The breakup fee for the Pfizer/Allergan merger would be $3.5bn in certain instances, but much lower, just $400m in expense reimbursement, if a party decides to terminate the deal due to an adverse change in law.